Biotest (BIO.DE) Stock Price
Biotest Price
Revenue has compounded at 6.1% per year over the past 19 years to 726.20 M EUR. Earnings per share have declined at 0.4% per year over the last 15 years. Biotest's net margin stands at 3.6%, up from -6.5% several years earlier.
Biotest stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biotest over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotest stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotest's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biotest Price |
|---|
Biotest Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotest Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 422.00 | 439.00 | 500.00 | 582.00 | 589.00 | 553.00 | 378.00 | 400.00 | 419.00 | 484.00 | 515.00 | 516.00 | 684.00 | 726.00 | 712.00 | 702.00 |
| 2.43 | 4.03 | 13.90 | 16.40 | 1.20 | -6.11 | -31.65 | 5.82 | 4.75 | 15.51 | 6.40 | 0.19 | 32.56 | 6.14 | -1.93 | -1.40 |
| 39.57 | 41.91 | 41.40 | 38.49 | 35.31 | 36.71 | 32.54 | 33.50 | 30.55 | 26.86 | 15.53 | 24.03 | 40.94 | 30.72 | 30.72 | 30.72 |
| 167.00 | 184.00 | 207.00 | 224.00 | 208.00 | 203.00 | 123.00 | 134.00 | 128.00 | 130.00 | 80.00 | 124.00 | 280.00 | 223.00 | 218.70 | 215.63 |
| 41.00 | 42.00 | 53.00 | 53.00 | 37.00 | 35.00 | -9.00 | 10.00 | 9.00 | -15.00 | -49.00 | -11.00 | 143.00 | 94.00 | 26.00 | 315.00 |
| 9.72 | 9.57 | 10.60 | 9.11 | 6.28 | 6.33 | -2.38 | 2.50 | 2.15 | -3.10 | -9.51 | -2.13 | 20.91 | 12.95 | 3.65 | 44.87 |
| 48.00 | 33.00 | 32.00 | 19.00 | -82.00 | -45.00 | -3.00 | 181.00 | -4.00 | -31.00 | -63.00 | -31.00 | 127.00 | 26.00 | 59.00 | 279.00 |
| 23.08 | -31.25 | -3.03 | -40.63 | -531.58 | -45.12 | -93.33 | -6,133.33 | -102.21 | 675.00 | 103.23 | -50.79 | -509.68 | -79.53 | 126.92 | 372.88 |
| 38.72 | 38.72 | 38.72 | 39.32 | 38.72 | 38.72 | 38.72 | 39.57 | 38.72 | 38.72 | 39.57 | 39.57 | 39.57 | 38.69 | 38.69 | 38.69 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biotest generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotest retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotest's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biotest has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotest's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biotest stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotest Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotest business model & stock analysis
Biotest SWOT Analysis
Strengths
Biotest AG boasts several key strengths that contribute to its success:
- Strong brand reputation and recognition in the pharmaceutical industry.
- Extensive experience and expertise in the development and manufacturing of biological and synthetic therapeutic drugs.
- Well-established distribution channels and strategic partnerships.
- Robust financial performance and steady revenue growth.
Biotest AG faces certain weaknesses and challenges that need to be addressed:
- Relatively small market share compared to larger competitors.
- Dependency on a limited product portfolio, which makes the company susceptible to market fluctuations.
- Limited geographical reach, primarily focused on European markets.
- High research and development costs that may impact profitability.
Biotest AG can leverage several opportunities to drive growth and development:
- Expansion into emerging markets, particularly in Asia and Latin America, to tap into the growing demand for pharmaceutical products.
- Development of new innovative therapies and drugs to address unmet medical needs.
- Strategic collaborations and acquisitions to enhance product portfolio and market presence.
- Increasing demand for plasma-derived products and therapies.
Biotest AG should be mindful of potential threats that may pose challenges to its operations:
- Intense competition from larger pharmaceutical companies with greater resources and market share.
- Stringent regulations and compliance requirements in the pharmaceutical industry.
- Economic instability and fluctuations in currency exchange rates.
- The possibility of product recalls or safety issues impacting the company's reputation.
Weaknesses
Biotest AG faces certain weaknesses and challenges that need to be addressed:
- Relatively small market share compared to larger competitors.
- Dependency on a limited product portfolio, which makes the company susceptible to market fluctuations.
- Limited geographical reach, primarily focused on European markets.
- High research and development costs that may impact profitability.
Biotest AG can leverage several opportunities to drive growth and development:
- Expansion into emerging markets, particularly in Asia and Latin America, to tap into the growing demand for pharmaceutical products.
- Development of new innovative therapies and drugs to address unmet medical needs.
- Strategic collaborations and acquisitions to enhance product portfolio and market presence.
- Increasing demand for plasma-derived products and therapies.
Biotest AG should be mindful of potential threats that may pose challenges to its operations:
- Intense competition from larger pharmaceutical companies with greater resources and market share.
- Stringent regulations and compliance requirements in the pharmaceutical industry.
- Economic instability and fluctuations in currency exchange rates.
- The possibility of product recalls or safety issues impacting the company's reputation.
Opportunities
Biotest AG can leverage several opportunities to drive growth and development:
- Expansion into emerging markets, particularly in Asia and Latin America, to tap into the growing demand for pharmaceutical products.
- Development of new innovative therapies and drugs to address unmet medical needs.
- Strategic collaborations and acquisitions to enhance product portfolio and market presence.
- Increasing demand for plasma-derived products and therapies.
Biotest AG should be mindful of potential threats that may pose challenges to its operations:
- Intense competition from larger pharmaceutical companies with greater resources and market share.
- Stringent regulations and compliance requirements in the pharmaceutical industry.
- Economic instability and fluctuations in currency exchange rates.
- The possibility of product recalls or safety issues impacting the company's reputation.
Threats
Biotest AG should be mindful of potential threats that may pose challenges to its operations:
- Intense competition from larger pharmaceutical companies with greater resources and market share.
- Stringent regulations and compliance requirements in the pharmaceutical industry.
- Economic instability and fluctuations in currency exchange rates.
- The possibility of product recalls or safety issues impacting the company's reputation.
Biotest Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biotest historical P/E ratio, EBIT multiple, and P/S ratio
Biotest annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biotest shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotest stock splits
Biotest Dividend History
17 years of dividend payments
Biotest dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Biotest stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Biotest shareholder structure
| % | Name |
|---|---|
49.62557% | |
0.06500% | |
0.03500% |
Biotest Beneficial Ownership Filings (SEC 13D/G)
Biotest Executives and Management Board
8 members · avg. age 61 · 13 % women
Mr. Peter Janssen (58)
Chairman of the Management Board, Chief Executive Officer
583,000.00 EUR
Management
Dr. Monika Buttkereit
Head of Investor Relations · since 2019
Board of Directors
Dr. Bernhard Ehmer (69)
Chairman of the Supervisory Board · since 2014
Mr. David Bell (70)
Member of the Supervisory Board
Mr. Juergen Heilmann (63)
Member of the Supervisory Board, Employee Representative
Mr. Dirk Schuck (46)
Member of the Supervisory Board, Employee Representative
Mr. Raimon Roura (61)
Member of the Supervisory Board
Prof. Dr. Gernot Hebestreit (62)
Member of the Supervisory Board
Biotest Supply Chain
Biotest Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.36 | 0.57 | 0.87 | ||
| 2 | 0.47 | -0.26 | 0.50 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.60 | -0.61 | -0.83 | ||
| 2 | 0.59 | -0.37 | -0.67 | ||
| 3 | 0.58 | 0.22 | -0.66 | ||
| 4 | Endo | 0.65 | -0.07 | -0.34 |
Frequently asked questions about Biotest
The business model of Biotest AG revolves around the development, production, and distribution of innovative biotherapeutic products. Biotest AG focuses on the areas of clinical immunology, hematology, and intensive care medicine. The company's primary goal is to provide patients with effective and safe treatments for various diseases and medical conditions. Biotest AG's portfolio includes plasma-derived and monoclonal antibody-based therapies. By leveraging their expertise in biotechnology, Biotest AG aims to contribute to improving patients' quality of life. With a strong dedication to research and development, the company continuously strives to introduce novel and advanced solutions in the field of biotherapeutics.
Biotest AG is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biotest AG in the market are CSL Behring, Grifols, and Octapharma. These companies also operate in the field of plasma protein therapies and pharmaceutical products, competing with Biotest AG in terms of product offerings, global reach, and market share.
Biotest AG is a leading biopharmaceutical company with a rich history and background. Founded in 1946, the company specializes in the development, production, and marketing of immunology and haematology products. Biotest AG has been at the forefront of medical innovation, focusing on therapeutics that cater to patients with severe immune deficiencies and haematological disorders. With a commitment to excellence and a strong research-driven approach, Biotest AG has established itself as a trusted name in the healthcare industry. Today, the company continues to provide life-saving treatments, leveraging its expertise and state-of-the-art facilities to improve patient outcomes around the world.
Biotest AG, a leading biotechnology company, has achieved several significant milestones in its corporate journey. Some noteworthy accomplishments include the successful completion of clinical trials for its innovative therapeutics and the subsequent approval of these products by regulatory authorities. Biotest AG has also secured strategic partnerships and collaborations with renowned pharmaceutical companies, enabling wider distribution and increased market reach for its offerings. Moreover, the company has consistently focused on research and development, resulting in the launch of cutting-edge treatment options that have revolutionized patient care in various therapeutic areas. These achievements testify to Biotest AG's commitment to advancing medical science and improving healthcare outcomes.
Biotest AG is primarily present in several countries and regions. The company has a strong presence in Germany, where its headquarters is located. It also has significant operations in Austria and Switzerland. Furthermore, Biotest AG has expanded its reach to other European countries such as France, Italy, and the United Kingdom. Additionally, the company has a strong presence in the United States, where it has established manufacturing facilities and distribution networks. With a global presence, Biotest AG continues to expand its market presence and deliver high-quality products and services to customers worldwide.
Biotest AG represents values of innovation, quality, and dedication in the field of biotechnology. The company's corporate philosophy revolves around delivering life-saving therapies and diagnostic tools to patients worldwide. Biotest AG is committed to advancing healthcare by developing and producing plasma proteins, blood clotting factors, and immunoglobulins. With a strong focus on research and development, Biotest AG strives to meet the highest standards of safety and efficacy in its products. The company's dedication to improving patient lives and constant pursuit of scientific excellence distinguishes Biotest AG in the biotechnology industry.
7 analysts currently rate the Biotest stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Biotest to generate revenue of 702.32 M EUR and earnings per share of 7.22 EUR.
The Biotest share (BIO.DE) is listed on 9 stock exchanges, including: XETRA (BIO.DE), Frankfurt (BIO.F), München (BIO.MU), Stuttgart (BIO.SG), Düsseldorf (BIO.DU), Berlin (BIO.BE), Hamburg (BIO.HM), London (0N6Z.L).
The Biotest AG is an international biotechnology company focused on the development, manufacturing, and distribution of biopharmaceutical products as well as reagents and diagnostics. The company operates worldwide with headquarters in Europe and the USA. The business model of Biotest is centered around developing and marketing innovative therapeutics and medical diagnostic solutions. The company serves different business areas such as hematology, immunology, and intensive care medicine. Within these areas, Biotest offers various product lines typically focused on plasma-based therapies. Among other things, the company offers immunoglobulins (antibodies), platelet preparations, coagulation factors, and albumin preparations that can be used in patients with certain blood disorders or immunodeficiencies. Additionally, Biotest also supplies plasma products and diagnostic products to medical facilities and laboratories worldwide. Another important business area is research and development. Through state-of-the-art technology and research methods, the company intensively researches the development of new therapeutic options and diagnostic solutions. The company is particularly committed to sustainable production and the highest possible product quality. Biotest therefore closely collaborates with partners around the world to enable global sourcing of blood plasma and ensure proximity to important production sites. The company relies on innovative manufacturing processes and continuous improvement of working and production conditions. In addition to manufacturing and marketing plasma products and diagnostics, Biotest is also involved in the development of therapy components based on innovative technologies such as nanoparticles, antibodies, or RNA. This usually involves targeted therapy for cancer, blood disorders, and autoimmune diseases. The success of Biotest's business model is reflected in constant growth and increasing demand for the company's products. Biotest is now a global biotechnology company specializing in the production of plasma products and diagnostics, characterized by a high degree of sustainability and innovative technologies. Continuous research and development of new therapy options and close collaboration with global partners are essential to the company's success and its employees. Biotest's goal is to provide patients worldwide with high-quality medications and diagnostic solutions, thereby contributing to enabling people to lead a healthy and fulfilling life.
The expected revenue of Biotest is 702.32 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biotest is 279.47 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Biotest at the moment.
The P/S cannot be calculated for Biotest currently.
The Eulerpool Quality Score for Biotest is 3/10.
The ISIN of Biotest is DE0005227201. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotest is 522720. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotest is BIO.DE. The ticker symbol is used to trade Biotest shares on the stock exchange.
The current dividend yield of Biotest is - %.
Biotest is assigned to the 'Health' sector.
The dividends of Biotest are distributed in EUR.
Biotest stock
Biotest Peer Group
Biotest Ticker
Biotest FIGI
All fundamentals and in-depth analysis of Biotest
Our stock analysis for Biotest stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.